Aurobindo Pharma witnessed an 8.6% YoY increase in net profit, reaching Rs 817 crore in Q2 FY25, driven by robust sales in Europe and growth markets. Despite a dip in US formulations revenue, the company’s overall revenue rose by 8% YoY.
| Subscribe To Our Free Newsletter |
